Patent ID: 8188234
Filing Date: 2012-05-29
Classification: A61K,A61P,C07K,C12N

Abstract:
1. An isolated PCSK9-specific antagonist antibody or antigen-binding portion thereof which comprises: (a) a heavy chain variable region comprising CDR1, 2 and 3 domains; said CDR1 domain comprising SEQ ID NO: 13; said CDR2 domain comprising SEQ ID NO: 15; and said CDR3 domain comprising SEQ ID NO: 17; and (b) a light chain variable region comprising CDR1, 2 and 3 domains; said CDR1 domain comprising SEQ ID NO: 3; said CDR2 domain comprising SEQ ID NO: 5, and said CDR3 domain comprising SEQ ID NO: 7; wherein said PCSK9-specific antagonist antagonizes PCSK9-mediated inhibition of cellular LDL uptake.